In particular, I was talking about ketamine in the context of depression—which often coexists in individuals who attempt suicide or commit suicidal acts—as compared to other, traditional antidepressants such as serotonin reuptake inhibitors and monoamine oxidase inhibitors. Those are traditional classes of antidepressants.
Those take weeks or months to kick in, and they do not effectively treat everybody, as we just heard from the panel. It has to be individualized, and we need to figure out a way.
The main point I was trying to make with ketamine is that not only does it have a fast-acting antidepressant action but it is an even stronger anti-suicidal ideation medication.